American Society of Hematology 2007

December 2007
BioWorld Today;12/11/2007, Vol. 18 Issue 239, p3
The article reports on the open-label clinical study conducted by Alexion Pharmaceuticals Inc. According to the Cheshire, Connecticut-based company, paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, was more likely for the general public to have than chronic kidney disease. Soliris, with eculizumab as its generic name, may be used to treat PNH.


Related Articles

  • Alexion Pharmaceuticals. Investor's Business Daily // Investors Business Daily;4/13/2015, pA02 

    The article focuses on the approval given to Alexion Pharmaceuticals Inc. (ALXN) which will allow update of the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients without history of transfusion.

  • LONG-TERM SOLIRIS TREATMENT IMPROVES KIDNEY FUNCTION.  // Biotech Business;Jan2010, Vol. 23 Issue 1, p1 

    The article reports on the findings of Alexion Pharmaceuticals, Inc. from its 26-week extension of the AEGIS study, an open-label registration study focused on showing Soliris as treatment for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). It affirmed that patients with...

  • ALEXION REACHES AGREEMENT WITH FDA FOR PHASE III ECULIZUMAB.  // Biotech Business;Sep2004, Vol. 17 Issue 9, p5 

    Reports on the agreement of the U.S. Food and Drug Administration on the protocols constituting the phase III program of Alexion Pharmaceuticals Incorporated for its drug eculizumab. Overview of the phase III trial program; Results of the first trial performed on patients with chronic orphan...

  • An Orphan's Tale. Comer, Ben // Medical Marketing & Media;Nov2009, Vol. 44 Issue 11, p48 

    The article offers information on Soliris, a drug manufactured and marketed by Alexion Pharmaceuticals Inc. in the U.S. It notes that the drug is monoclonal antibody indicated for the treatment of paroxysman nocturnal hemoglobinuria (PNH) and was designated an orphan drug by the U.S. Food and...

  • EARNINGS ROUNDUP.  // BioWorld Today;10/27/2008, Vol. 19 Issue 209, p3 

    The article reports that Alexion Pharmaceuticals Inc. of Cheshire, Connecticut reported total revenue of $76.5 million for the third quarter of 2008. According to the article, this came from sales of paroxysmal nocturnal hemoglobinuria drug Soliris which were up from the $21.8 milion in revenues...

  • Soliris on life-saving program.  // Australian Journal of Pharmacy;Feb2011, Vol. 92 Issue 1089, p38 

    The article offers information on Soliris (ecuilizumab), a drug indicated to intervene a blood disease called paroxysmal nocturnal haemoglobinuria (PNH).

  • ASH 2008.  // BioWorld Today;12/9/2008, Vol. 19 Issue 238, p7 

    The article reports on the announcement by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut, that Soliris or eculizumab, a terminal complement inhibitor used in treating paroxysmal nocturnal hemoglobinuria (PNH), was associated with improved hematologic parameters. In one patient with cold...

  • New biologic: Soliris.  // Formulary;Apr2007, Vol. 42 Issue 4, p215 

    The article reports on the approval of recombinant monoclonal antibody eculizumab from Alexion Pharmaceuticals Inc. for the treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis. Its efficacy is evaluated in a randomized placebo-controlled 26-week study, and a single-arm 52-week...

  • CHMP ADOPTS POSITIVE OPINION FOR ALEXION'S SOLIRIS IN EUROPE.  // Worldwide Biotech;Jun2007, Vol. 19 Issue 6, p5 

    The article reports that the Committee for Human Medicinal Products of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Soliris, a drug from Alexion Pharmaceuticals Inc. The drug is for patients with paroxysmal nocturnal hemoglobinuria (PNH)....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics